Tag: Respirion Pharmaceuticals
Partnership between WA, Brandon BioCatalyst set to continue
The Western Australian government announced an additional $2.31 million for a further seven years, or until 2029, to continue its support for life science investment fund Brandon BioCatalyst, to which it has given $2.52 million since 2008.
Featured Article
AMCA Impact Study highlights AI’s role in improving HVAC safety compliance
A new AMCA Impact Study has highlighted the growing challenge of helping HVAC contractors access reliable safety and compliance information quickly, particularly for small and medium-sized businesses operating in Australia's highly regulated construction environment.
